Two of these drugs, Cixutumumab and Bevacizumab, each target a single gene that controls important biological processes for tumor progression: cellular proliferation by inhibiting IGF1R and vascularization by inhibiting VEGFA, respectively. Here, IGF1R is linked to neoplasm.